The Next Wave of Healthcare Innovation: Top Diagnostics Sectors Set to Boom Through 2030

11 May 2026 • by Natalie Aster

The diagnostics industry is moving from a reactive testing model to a faster, more precise, and more decentralized healthcare infrastructure. Hospitals, laboratories, insurers, pharmaceutical companies, and digital health platforms are investing in diagnostics that detect disease earlier, guide targeted therapies, shorten treatment delays, and reduce the cost of unnecessary procedures. The global in vitro diagnostics market alone is estimated at more than USD 100 billion in the year 2025, with forecasts pointing to continued expansion through 2030 and beyond. 

The strongest opportunities are concentrated in segments where testing is becoming faster, more automated, more personalized, and easier to access outside centralized labs. Below are the diagnostics sectors most likely to shape the next five years.

Molecular Diagnostics: The Engine of Precision Testing

Molecular diagnostics is one of the most important growth engines in healthcare testing because it can identify disease at the genetic, RNA, or pathogen-specific level. Unlike traditional diagnostics that often detect downstream symptoms or broad biological signals, molecular platforms can reveal specific mutations, viral loads, antimicrobial resistance markers, and inherited risk factors.

This sector is expanding because healthcare systems increasingly need tests that support precision medicine. In cancer care, molecular diagnostics helps identify actionable mutations and match patients with targeted therapies. In infectious disease, it enables faster pathogen identification and can reduce unnecessary antibiotic use. The molecular diagnostics market is slated to rise from USD 20.3 billion in 2025 to USD 42.6 billion by 2030, representing a 13.1% CAGR in the next 5 years.

Point-of-Care Diagnostics: Faster Answers Where Patients Are Treated

Point-of-care diagnostics is becoming a critical part of modern healthcare because patients and clinicians increasingly expect results during the same visit. These tests are used in urgent care centers, physician offices, ambulances, pharmacies, retail clinics, long-term care facilities, and home-health settings.

The appeal is simple: faster diagnosis can mean faster treatment. For respiratory infections, cardiac markers, glucose monitoring, pregnancy testing, coagulation testing, and infectious disease screening, point-of-care tools reduce dependence on centralized lab turnaround times. Recent market estimates point to strong demand through 2030: the point-of-care diagnostics market is projected to exceed USD 43.1 billion by 2030.

Oncology Diagnostics & Early Cancer Screening

Cancer diagnostics is moving rapidly from late-stage detection toward earlier, less invasive screening. The most commercially attractive areas include colorectal cancer screening, breast cancer recurrence testing, liquid biopsy, companion diagnostics, minimal residual disease monitoring, and multi-cancer early detection.

Large strategic deals show how valuable this segment has become. Abbott’s planned acquisition of Exact Sciences, valued at up to USD 23 billion including debt, highlights the growing importance of cancer screening products such as Cologuard and Oncotype DX within broader diagnostics portfolios. 

The next wave of oncology diagnostics will be shaped by blood-based testing, AI-assisted pathology, genomic profiling, and tests that help physicians choose or adjust therapy earlier in the treatment journey.

Companion Diagnostics: The Commercial Backbone of Personalized Medicine

Companion diagnostics are tests used to determine whether a patient is likely to benefit from a specific therapy. Their role is growing because drug development is becoming more targeted, particularly in oncology, immunology, rare diseases, and genetic disorders.

For pharmaceutical companies, companion diagnostics can improve trial design, identify responsive patient populations, and support regulatory approval. For clinicians, they reduce guesswork. For patients, they improve the likelihood that treatment is matched to the biology of the disease. As more therapies require biomarker testing before prescribing, companion diagnostics will become deeply embedded in specialty care.

AI-Powered Diagnostic Imaging

Diagnostic imaging remains essential in healthcare, but its next phase of growth will come from artificial intelligence, workflow automation, image reconstruction, and decision-support tools. MRI, CT, ultrasound, mammography, and X-ray systems are increasingly being paired with AI algorithms that detect abnormalities, prioritize urgent cases, reduce reading time, and improve consistency.

The strongest opportunities are in radiology departments facing workforce shortages and rising imaging volumes. AI will not replace radiologists, but it will reshape how imaging data is triaged, interpreted, and integrated into clinical decision-making.

Digital Pathology & AI-Assisted Tissue Diagnostics

Pathology is undergoing a digital transition similar to radiology. Glass slides are being converted into high-resolution digital images, allowing pathologists to review cases remotely, use AI-based image analysis, and collaborate across institutions.

Digital pathology is especially important in oncology, where tissue analysis determines diagnosis, tumor grading, biomarker expression, and treatment strategy. AI tools can help identify subtle patterns, quantify biomarkers, and reduce subjectivity in complex cases. As hospitals modernize pathology labs, this sector is likely to see sustained investment.

Infectious Disease Diagnostics Beyond COVID-19

The pandemic accelerated investment in infectious disease testing, but the long-term opportunity extends far beyond COVID-19. Respiratory panels, sexually transmitted infection testing, antimicrobial resistance detection, tuberculosis diagnostics, sepsis testing, and hospital-acquired infection surveillance are all high-value areas.

Healthcare systems need rapid tests that distinguish viral from bacterial infections, identify resistance markers, and support public health monitoring. Multiplex testing platforms that detect multiple pathogens from a single sample are especially attractive because they improve efficiency and clinical usefulness.

Home Diagnostics & Consumer Testing

Home diagnostics is shifting from simple consumer tests to more clinically meaningful health monitoring. Blood collection kits, at-home sample collection, continuous glucose monitoring, fertility testing, microbiome testing, and remote patient monitoring are making diagnostics more accessible.

The strongest commercial opportunities will come from tests that combine convenience with reliable clinical interpretation. Consumers want actionable results, while healthcare providers want tests that integrate into care pathways. Companies that combine home collection, digital reporting, physician review, and follow-up care will be better positioned than firms offering isolated test kits.

Biomarker Testing for Chronic Disease Management

Chronic diseases account for a large share of healthcare spending, and diagnostics plays a central role in prevention, monitoring, and treatment adjustment. Biomarkers for cardiovascular disease, diabetes, kidney disease, autoimmune disorders, neurodegenerative disease, and metabolic health are gaining importance.

The growth opportunity is not only in discovering new biomarkers, but also in making existing biomarkers easier to measure more frequently. As value-based care expands, payers and providers will prioritize diagnostics that prevent hospitalizations, identify deterioration earlier, and guide lower-cost interventions.

The Bottom Line: Diagnostics Is Becoming Faster, Smarter & More Personalized

The diagnostics sectors most likely to boom through 2030 share a common theme: they deliver earlier answers, closer to the patient, with more clinical precision. Molecular diagnostics, point-of-care testing, oncology screening, companion diagnostics, AI imaging, digital pathology, infectious disease platforms, home testing, and biomarker-based chronic disease monitoring are no longer isolated niches. They are becoming the foundation of a more predictive healthcare system.

The winners in this market will be companies that combine scientific accuracy with speed, automation, clinical workflow integration, and scalable access. Diagnostics is no longer just a laboratory function. It is becoming one of the most important decision-making layers in modern medicine.

At Market Publishers you’ll find a rich collection of insightful research studies featuring various markets. Simply use the search form to find the report you need.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +357 96 030 922
 [email protected]
 MarketPublishers.com